Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers

Robert A. Kroll, Michael A. Pagel, Leslie Muldoon, Simon Roman-Goldstein, Steven A. Fiamengo, Edward Neuwelt

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

OBJECTIVE: To compare transient blood-brain barrier disruption (BBBD) by hypertonic mannitol with pharmacological modification of the blood-tumor barrier by the vasoactive peptide bradykinin for delivery of small and large agents to nude rat intracerebral xenografts. METHODS: Female nude rats (n = 104) with 6-day intracerebral human small cell lung carcinoma tumors were treated using BBBD (n = 24), intracarotid bradykinin (n = 38), or saline (controls, n = 32) administered intra-arterially. During or immediately after infusion, the rats were given radiolabeled agent (methotrexate or dextran 70; Dupont NEN, Boston, MA). The rats were killed 10 minutes later, and samples of tumor and brain regions were obtained for scintillation counting. Twenty- two additional rats were examined using magnetic resonance imaging after administering one of two contrast agents (gadoteridol or iron oxide nanoparticles) or saline (controls) in conjunction with BBBD or bradykinin. RESULTS: After BBBD, the delivery of both small (methotrexate) and large (dextran 70) radiolabeled tracers was increased 2- to 6-fold in the tumor and 3- to 20-fold in surrounding brain, as compared with saline controls. After bradykinin treatment, there was minimal change in delivery of methotrexate or dextran 70 to tumor and brain around tumor, with the greatest increase less than 60% over controls. Magnetic resonance imaging demonstrated increased delivery of both small and large contrast agents to the treated hemisphere after BBBD. In comparison, no increased tumor enhancement could be detected after bradykinin treatment. CONCLUSION: BBBD resulted in global delivery of a variety of agents in a wide range of sizes. In this human brain tumor xenograft model, bradykinin was not effective at increasing delivery to the tumor of any agent tested.

Original languageEnglish (US)
Pages (from-to)879-885
Number of pages7
JournalNeurosurgery
Volume43
Issue number4
DOIs
StatePublished - Oct 1998

Fingerprint

Bradykinin
Blood-Brain Barrier
Brain Neoplasms
Rodentia
Brain
Dextrans
Methotrexate
Pharmaceutical Preparations
Nude Rats
Neoplasms
Heterografts
Contrast Media
Magnetic Resonance Imaging
Scintillation Counting
Small Cell Lung Carcinoma
Mannitol
Nanoparticles
Pharmacology
Peptides

Keywords

  • Blood-brain barrier
  • Bradykinin
  • Brain neoplasm
  • Drug delivery
  • Mannitol

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model : A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. / Kroll, Robert A.; Pagel, Michael A.; Muldoon, Leslie; Roman-Goldstein, Simon; Fiamengo, Steven A.; Neuwelt, Edward.

In: Neurosurgery, Vol. 43, No. 4, 10.1998, p. 879-885.

Research output: Contribution to journalArticle

@article{49ac6d612aae4896ad2a36c409e4137c,
title = "Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers",
abstract = "OBJECTIVE: To compare transient blood-brain barrier disruption (BBBD) by hypertonic mannitol with pharmacological modification of the blood-tumor barrier by the vasoactive peptide bradykinin for delivery of small and large agents to nude rat intracerebral xenografts. METHODS: Female nude rats (n = 104) with 6-day intracerebral human small cell lung carcinoma tumors were treated using BBBD (n = 24), intracarotid bradykinin (n = 38), or saline (controls, n = 32) administered intra-arterially. During or immediately after infusion, the rats were given radiolabeled agent (methotrexate or dextran 70; Dupont NEN, Boston, MA). The rats were killed 10 minutes later, and samples of tumor and brain regions were obtained for scintillation counting. Twenty- two additional rats were examined using magnetic resonance imaging after administering one of two contrast agents (gadoteridol or iron oxide nanoparticles) or saline (controls) in conjunction with BBBD or bradykinin. RESULTS: After BBBD, the delivery of both small (methotrexate) and large (dextran 70) radiolabeled tracers was increased 2- to 6-fold in the tumor and 3- to 20-fold in surrounding brain, as compared with saline controls. After bradykinin treatment, there was minimal change in delivery of methotrexate or dextran 70 to tumor and brain around tumor, with the greatest increase less than 60{\%} over controls. Magnetic resonance imaging demonstrated increased delivery of both small and large contrast agents to the treated hemisphere after BBBD. In comparison, no increased tumor enhancement could be detected after bradykinin treatment. CONCLUSION: BBBD resulted in global delivery of a variety of agents in a wide range of sizes. In this human brain tumor xenograft model, bradykinin was not effective at increasing delivery to the tumor of any agent tested.",
keywords = "Blood-brain barrier, Bradykinin, Brain neoplasm, Drug delivery, Mannitol",
author = "Kroll, {Robert A.} and Pagel, {Michael A.} and Leslie Muldoon and Simon Roman-Goldstein and Fiamengo, {Steven A.} and Edward Neuwelt",
year = "1998",
month = "10",
doi = "10.1097/00006123-199810000-00090",
language = "English (US)",
volume = "43",
pages = "879--885",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model

T2 - A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers

AU - Kroll, Robert A.

AU - Pagel, Michael A.

AU - Muldoon, Leslie

AU - Roman-Goldstein, Simon

AU - Fiamengo, Steven A.

AU - Neuwelt, Edward

PY - 1998/10

Y1 - 1998/10

N2 - OBJECTIVE: To compare transient blood-brain barrier disruption (BBBD) by hypertonic mannitol with pharmacological modification of the blood-tumor barrier by the vasoactive peptide bradykinin for delivery of small and large agents to nude rat intracerebral xenografts. METHODS: Female nude rats (n = 104) with 6-day intracerebral human small cell lung carcinoma tumors were treated using BBBD (n = 24), intracarotid bradykinin (n = 38), or saline (controls, n = 32) administered intra-arterially. During or immediately after infusion, the rats were given radiolabeled agent (methotrexate or dextran 70; Dupont NEN, Boston, MA). The rats were killed 10 minutes later, and samples of tumor and brain regions were obtained for scintillation counting. Twenty- two additional rats were examined using magnetic resonance imaging after administering one of two contrast agents (gadoteridol or iron oxide nanoparticles) or saline (controls) in conjunction with BBBD or bradykinin. RESULTS: After BBBD, the delivery of both small (methotrexate) and large (dextran 70) radiolabeled tracers was increased 2- to 6-fold in the tumor and 3- to 20-fold in surrounding brain, as compared with saline controls. After bradykinin treatment, there was minimal change in delivery of methotrexate or dextran 70 to tumor and brain around tumor, with the greatest increase less than 60% over controls. Magnetic resonance imaging demonstrated increased delivery of both small and large contrast agents to the treated hemisphere after BBBD. In comparison, no increased tumor enhancement could be detected after bradykinin treatment. CONCLUSION: BBBD resulted in global delivery of a variety of agents in a wide range of sizes. In this human brain tumor xenograft model, bradykinin was not effective at increasing delivery to the tumor of any agent tested.

AB - OBJECTIVE: To compare transient blood-brain barrier disruption (BBBD) by hypertonic mannitol with pharmacological modification of the blood-tumor barrier by the vasoactive peptide bradykinin for delivery of small and large agents to nude rat intracerebral xenografts. METHODS: Female nude rats (n = 104) with 6-day intracerebral human small cell lung carcinoma tumors were treated using BBBD (n = 24), intracarotid bradykinin (n = 38), or saline (controls, n = 32) administered intra-arterially. During or immediately after infusion, the rats were given radiolabeled agent (methotrexate or dextran 70; Dupont NEN, Boston, MA). The rats were killed 10 minutes later, and samples of tumor and brain regions were obtained for scintillation counting. Twenty- two additional rats were examined using magnetic resonance imaging after administering one of two contrast agents (gadoteridol or iron oxide nanoparticles) or saline (controls) in conjunction with BBBD or bradykinin. RESULTS: After BBBD, the delivery of both small (methotrexate) and large (dextran 70) radiolabeled tracers was increased 2- to 6-fold in the tumor and 3- to 20-fold in surrounding brain, as compared with saline controls. After bradykinin treatment, there was minimal change in delivery of methotrexate or dextran 70 to tumor and brain around tumor, with the greatest increase less than 60% over controls. Magnetic resonance imaging demonstrated increased delivery of both small and large contrast agents to the treated hemisphere after BBBD. In comparison, no increased tumor enhancement could be detected after bradykinin treatment. CONCLUSION: BBBD resulted in global delivery of a variety of agents in a wide range of sizes. In this human brain tumor xenograft model, bradykinin was not effective at increasing delivery to the tumor of any agent tested.

KW - Blood-brain barrier

KW - Bradykinin

KW - Brain neoplasm

KW - Drug delivery

KW - Mannitol

UR - http://www.scopus.com/inward/record.url?scp=0031720748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031720748&partnerID=8YFLogxK

U2 - 10.1097/00006123-199810000-00090

DO - 10.1097/00006123-199810000-00090

M3 - Article

C2 - 9766316

AN - SCOPUS:0031720748

VL - 43

SP - 879

EP - 885

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -